Skip to main content
MedoxyMedoxyHealthcare Pvt Ltd

Terms & Disclaimer

Terms of Use

Terms for using Medoxy Healthcare Pvt Ltd's B2B catalogue, articles, and inquiry forms. Last updated 14 August 2026.

B2B website scope

This website provides company, catalogue, trade-quality, and inquiry information for distributors, healthcare organizations, institutions, and other qualified business contacts. Access to a page does not create an agency, distribution, supply, advisory, or other commercial relationship.

No medical advice

Catalogue and editorial content is not a substitute for professional medical advice, diagnosis, treatment, prescribing guidance, or approved product information. Clinical and patient-use questions require an appropriately qualified healthcare professional and current product-specific records.

No ecommerce or supply offer

The website does not provide online medicine sales, pricing, cart, checkout, payments, or direct consumer ordering. A listing or inquiry response does not by itself constitute an offer, guarantee of availability, authorization for a market, or acceptance of commercial terms.

Verify current product information

Names, compositions, dosage forms, images, packaging, availability, classification, and documentation may change or differ by market. Verify the exact product and current controlled records before a regulatory, clinical, procurement, or commercial decision.

No blanket certification claim

A general reference to quality, compliance, or an external guideline does not establish that Medoxy, a vendor, facility, product, or transaction has a particular licence, approval, certification, audit status, or endorsement. Request evidence applicable to the defined transaction.

Inquiry service

You are responsible for providing accurate, relevant information and for avoiding patient data or unnecessary sensitive information. A submission is received only when the service confirms successful delivery; a response time, commercial outcome, or continued availability of the form is not guaranteed.

Editorial sources

External sources are cited to support specific informational points and do not endorse Medoxy. Official material can change, and users should consult the current primary source and qualified professional advice for their circumstances.

Third-party services

External links, maps, social networks, and delivery or analytics providers are operated by third parties under their own terms. Medoxy does not control their availability or content.

Acceptable use

Do not misuse the website, attempt unauthorized access, disrupt its operation, submit unlawful or misleading content, impersonate another person or organization, or use automated submissions to burden the service.

Updates and contact

These terms may be updated with the website or business inquiry process. Last updated 14 August 2026. Questions can be sent to Medoxyhealthcarellp@gmail.com.

Medoxy Healthcare Pvt Ltd is a B2B pharmaceutical trading company based in Gurgaon, Haryana, India, focused on a gastroenterology product catalogue for distributors, stockists, hospitals, institutions, and other qualified healthcare businesses. The product catalogue lists brand names, compositions, dosage forms, and pack sizes across categories such as proton pump inhibitor combinations, antispasmodics, ursodeoxycholic acid, rifaximin, probiotics, antacid and alginate suspensions, and nutritional supplements.

Catalogue entries include Benzispa SR (Mebeverine Hydrochloride Sustained Release), Benzispa Plus (Mebeverine + Chlordiazepoxide), Esomizole-D (Esomeprazole (EC) + Domperidone (SR)), Ursofiz 300 (Ursodeoxycholic Acid IP 300 mg), Ushield (Sucralfate + Oxetacaine), Esomizole-40 (Esomeprazole 40 mg with Sodium Bicarbonate as buffer), Edoflora (Lyophilized Saccharomyces boulardii 250 mg), Menzovit (Multivitamin, Multimineral, Antioxidants, Iron & Zinc), Finozyme Q10 (Coenzyme Q10 + L-Arginine + Omega-3 fatty acid + Selenium + Lycopene), Esomizole-IT (Esomeprazole (EC) + Itopride (SR)), Ursofiz 450 (Ursodeoxycholic Acid Sustained Release), U Raft (Sodium Alginate + Sodium Bicarbonate + Calcium Carbonate), Rifadoxy 400 (Rifaximin IP 400 mg) and Rifadoxy 550 (Rifaximin IP 550 mg). Names, compositions, images, packaging, and availability may change or differ by market. Verify the exact product and current documents before any regulatory, procurement, or commercial decision.

1. Website content is provided for business and informational purposes only and is not a substitute for professional medical advice, diagnosis, treatment, or approved prescribing information. Patients should consult a qualified healthcare professional.

2. This website does not sell medicines online, display pricing, or accept consumer orders. A listing or inquiry response is not an offer of supply or a guarantee of availability. Terms apply.

3. References to quality, compliance, or external guidelines do not by themselves establish a particular licence, approval, or certification. Evidence applicable to a defined transaction can be requested through the trade inquiry form. See Trade & Quality and Compliance for more information.

Articles on the Healthcare Insights blog follow our content policy. Personal data submitted through inquiry forms is handled as described in the privacy policy.